• Yesterday, 7:06 AM
    • PharmAthene (NYSEMKT:PIP) and privately held Altimmune ink an agreement to merge in an all-stock transaction. Under the terms of the deal, Altimmune will become a wholly owned subsidiary of PharmAthene although Altimmune shareholders will own 58.2% of the shares in the combined company. Shares will trade on the NYSE MKT under the symbol "ALT."
    • Altimmune CEO Bill Enright and CFO and EVP of Corporate Development Elizabeth Czerepak will continue to serve in their roles in the post-merger organization which should have ~$20M in quick assets.
    • The transaction will not affect PIP's previously announced one-time cash dividend of $2.91 per common share.
    Yesterday, 7:06 AM | 12 Comments
  • Dec. 2, 2013, 1:53 PM
    • PharmAthene (PIP +1.6%)┬áterminates an agreement that called for a subsidiary to merge with Theraclone in an all-stock deal.
    • PIP will pay Theraclone a $1M termination fee. (PR)
    Dec. 2, 2013, 1:53 PM | 1 Comment